WO2008030524A3 - Liquid pharmaceutical formulations for oral administration of a cgrp antagonist - Google Patents
Liquid pharmaceutical formulations for oral administration of a cgrp antagonist Download PDFInfo
- Publication number
- WO2008030524A3 WO2008030524A3 PCT/US2007/019461 US2007019461W WO2008030524A3 WO 2008030524 A3 WO2008030524 A3 WO 2008030524A3 US 2007019461 W US2007019461 W US 2007019461W WO 2008030524 A3 WO2008030524 A3 WO 2008030524A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral administration
- pharmaceutical formulations
- liquid pharmaceutical
- cgrp antagonist
- oxo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009527409A JP2010502710A (en) | 2006-09-08 | 2007-09-06 | Liquid pharmaceutical formulation for oral administration of CGRP antagonist |
EP07837821A EP2063708A2 (en) | 2006-09-08 | 2007-09-06 | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
CA002662748A CA2662748A1 (en) | 2006-09-08 | 2007-09-06 | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
AU2007293032A AU2007293032A1 (en) | 2006-09-08 | 2007-09-06 | Liquid pharmaceutical formulations for oral administration of a CGRP antagonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84305206P | 2006-09-08 | 2006-09-08 | |
US60/843,052 | 2006-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008030524A2 WO2008030524A2 (en) | 2008-03-13 |
WO2008030524A3 true WO2008030524A3 (en) | 2008-10-02 |
Family
ID=39157840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/019461 WO2008030524A2 (en) | 2006-09-08 | 2007-09-06 | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2063708A2 (en) |
JP (1) | JP2010502710A (en) |
CN (1) | CN101511184A (en) |
AU (1) | AU2007293032A1 (en) |
CA (1) | CA2662748A1 (en) |
WO (1) | WO2008030524A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011526909A (en) * | 2008-06-30 | 2011-10-20 | メルク・シャープ・エンド・ドーム・コーポレイション | Telkagepanto potassium solid dosage formulation |
CN101756900B (en) * | 2010-02-25 | 2012-05-30 | 谢恬 | Elemene micro-emulsion |
AU2014318741B2 (en) * | 2013-09-16 | 2018-12-06 | Merck Sharp & Dohme Llc | Formulations for CGRP receptor antagonists |
WO2015164657A1 (en) * | 2014-04-23 | 2015-10-29 | Bcs Business Consulting Services Pte Ltd | Incorporation of water soluble component(s) into anhydrous formulations |
EA202192792A1 (en) * | 2019-04-11 | 2022-01-11 | Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи | COMPOSITION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH WEAK PERMEABILITY |
WO2023220109A1 (en) * | 2022-05-11 | 2023-11-16 | Eli Lilly And Company | Glp1 pharmaceutical compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
WO2004092166A2 (en) * | 2003-04-15 | 2004-10-28 | Merck & Co., Inc. | Cgrp receptor antagonists |
-
2007
- 2007-09-06 CN CNA2007800330974A patent/CN101511184A/en active Pending
- 2007-09-06 EP EP07837821A patent/EP2063708A2/en not_active Withdrawn
- 2007-09-06 CA CA002662748A patent/CA2662748A1/en not_active Abandoned
- 2007-09-06 JP JP2009527409A patent/JP2010502710A/en not_active Withdrawn
- 2007-09-06 WO PCT/US2007/019461 patent/WO2008030524A2/en active Application Filing
- 2007-09-06 AU AU2007293032A patent/AU2007293032A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
WO2004092166A2 (en) * | 2003-04-15 | 2004-10-28 | Merck & Co., Inc. | Cgrp receptor antagonists |
Also Published As
Publication number | Publication date |
---|---|
CN101511184A (en) | 2009-08-19 |
EP2063708A2 (en) | 2009-06-03 |
WO2008030524A2 (en) | 2008-03-13 |
AU2007293032A1 (en) | 2008-03-13 |
JP2010502710A (en) | 2010-01-28 |
CA2662748A1 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008030524A3 (en) | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist | |
WO2007048026A3 (en) | Cgrp peptide antagonists and conjugates | |
WO2007133752A3 (en) | Formulations of 5-ht3 receptor antagonists with polyorthoester for use in the prevention of acute and delayed chemotherapy- induced nausea and vomiting (cinv) | |
WO2005112633A3 (en) | Compounds and compositions for delivering active agents | |
UA97653C2 (en) | Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability | |
WO2005065319A3 (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
WO2005065317A3 (en) | Effervescent oral fentanyl dosage form | |
TWI365880B (en) | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp | |
UA101313C2 (en) | Normal;heading 1;heading 2;heading 3;WEEKLY ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | |
IL195788A (en) | Ophthalmic formulation of vascular endothelial growth factor antagonist, a method of producing the same and syringe suitable for intravitreal administration comprising the same | |
WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
RS54904B1 (en) | Antibacterial pharmaceutical compositions | |
HK1160827A1 (en) | Method for filling medicament vial | |
WO2008019996A3 (en) | Formulations of flibanserin and method for manufacturing the same | |
WO2005117873A3 (en) | Compositions containing opioid antagonists | |
TW200716157A (en) | Pharmaceutical formulations and methods of treatment using the same | |
WO2007143155A3 (en) | Sustained release pharmaceutical dosage form containing phenylephrine | |
NZ581589A (en) | Solubilized sterile injectable formulation of docetaxel without Tween 80 | |
WO2005076829A3 (en) | Stable loratadine spill resistant formulation | |
WO2005117895A3 (en) | Compositions comprising meloxicam | |
EA200870545A1 (en) | NEW HETEROCYCLIC COMPOUNDS | |
WO2006050002A3 (en) | Compositions for controlled delivery of pharmaceutically active compounds | |
IL176116A0 (en) | Cryogranulation and storage method for active pharmaceutical agents | |
WO2004032866A3 (en) | Therapeutic formulations | |
IL197732A0 (en) | Packaging system for pharmaceutical compositions for intravenous administration and kits comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780033097.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07837821 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007293032 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1014/CHENP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2007293032 Country of ref document: AU Date of ref document: 20070906 Kind code of ref document: A Ref document number: 2662748 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009527409 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007837821 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |